Skip to main content

Peer Review reports

From: Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

Original Submission
24 Feb 2022 Submitted Original manuscript
5 Apr 2022 Author responded Author comments - Kai Shang
Resubmission - Version 2
5 Apr 2022 Submitted Manuscript version 2
5 Jul 2022 Reviewed Reviewer Report
2 Aug 2022 Reviewed Reviewer Report
27 Sep 2022 Author responded Author comments - Kai Shang
Resubmission - Version 3
27 Sep 2022 Submitted Manuscript version 3
25 Oct 2022 Reviewed Reviewer Report
28 Nov 2022 Author responded Author comments - Kai Shang
Resubmission - Version 4
28 Nov 2022 Submitted Manuscript version 4
Publishing
30 Nov 2022 Editorially accepted
12 Dec 2022 Article published 10.1186/s12885-022-10391-z

You can find further information about peer review here.

Back to article page